ArticleJournal of computer-aided molecular design2025
Computational and experimental repositioning of quinoline analogues as KSP inhibitors: insights from free energy landscape and PCA analysis.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular Dynamics Simulations Provide Further Insights into the Allosteric Regulation of the Kinesin-5 Motor Domain by Loop 5.Journal of chemical information and modeling · 2026Article
- Evaluation of New Coumarins for Anti-Cancer Activity in HL-60 Cell Line Supported by Molecular Docking, MD Simulation, and Binding Free Energy Calculations.OncoTargets and therapy · 2026Article
- Decoding the molecular mechanism via systems biology-based insights into neoschaftoside from Ailanthus altissima targeting lung cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Eg5 is a mitotic kinesin motor protein essential for the formation of bipolar spindles during cell division. Its inhibition disrupts mitosis, leading to cell cycle arrest and apoptosis in cancer cells. This makes Eg5 a promising target for chemotherapeutic interventions, especially in cases resistant to traditional treatments. In this study, a drug repurposing strategy was employed to design and synthesise quinoline-based Schiff base derivatives as potential Eg5 inhibitors. These compounds were subjected to in vitro biological evaluations, including cytotoxicity testing against the human breast cancer cell line MDA-MB-231 and the normal mouse fibroblast cell line L929 using the MTT assay. Enzymatic assays targeting Eg5 were also conducted. Among the synthesised molecules, compound (5) demonstrated significant Eg5 inhibition in enzymatic assays, with an IC
Indexed as
Identifiers
40794230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.